Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
91 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Oral Mucositis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides an overview of the Oral Mucositis (Oncology) pipeline landscape. Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oral Mucositis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Oral Mucositis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Oral Mucositis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Oncology). - The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Oral Mucositis (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Oral Mucositis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Figures Introduction Global Markets Direct Report Coverage Oral Mucositis - Overview Oral Mucositis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Oral Mucositis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Oral Mucositis - Companies Involved in Therapeutics Development Cellceutix Corp Clevexel Pharma SA Colby Pharmaceutical Company Galera Therapeutics Inc Humanetics Corp Onxeo SA Oragenics Inc Otsuka Holdings Co Ltd Soligenix Inc Spectrum Pharmaceuticals Inc Spherium Biomed SL Oral Mucositis - Drug Profiles AG-013 - Drug Profile Product Description Mechanism Of Action R&D Progress BCD-600 - Drug Profile Product Description Mechanism Of Action R&D Progress BIO-300 - Drug Profile Product Description Mechanism Of Action R&D Progress brilacidin tetrahydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress clonidine hydrochloride ER - Drug Profile Product Description Mechanism Of Action R&D Progress CVXL-0095 - Drug Profile Product Description Mechanism Of Action R&D Progress dusquetide - Drug Profile Product Description Mechanism Of Action R&D Progress GC-4419 - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy for Oral Mucositis - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate SOD2 for Oral Mucositis - Drug Profile Product Description Mechanism Of Action R&D Progress GM-0111 - Drug Profile Product Description Mechanism Of Action R&D Progress HYLP-006 - Drug Profile Product Description Mechanism Of Action R&D Progress KIN-219 - Drug Profile Product Description Mechanism Of Action R&D Progress melatonin - Drug Profile Product Description Mechanism Of Action R&D Progress pralatrexate - Drug Profile Product Description Mechanism Of Action R&D Progress rebamipide - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Oral Mucositis - Dormant Projects Oral Mucositis - Discontinued Products Oral Mucositis - Product Development Milestones Featured News & Press Releases Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients Dec 12, 2016: Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency Dec 08, 2016: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis Dec 08, 2016: Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients Nov 21, 2016: U.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis Oct 26, 2016: Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications Oct 18, 2016: Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients Sep 27, 2016: Galera Therapeutics Announces Presentation of One-Year Follow-up Data from a Phase 1b/2a Study of GC4419 In the Reduction of Severe Oral Mucositis Sep 06, 2016: Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs Aug 30, 2016: Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Oral Mucositis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Oral Mucositis - Pipeline by Cellceutix Corp, H1 2017 Oral Mucositis - Pipeline by Clevexel Pharma SA, H1 2017 Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H1 2017 Oral Mucositis - Pipeline by Galera Therapeutics Inc, H1 2017 Oral Mucositis - Pipeline by Humanetics Corp, H1 2017 Oral Mucositis - Pipeline by Onxeo SA, H1 2017 Oral Mucositis - Pipeline by Oragenics Inc, H1 2017 Oral Mucositis - Pipeline by Otsuka Holdings Co Ltd, H1 2017 Oral Mucositis - Pipeline by Soligenix Inc, H1 2017 Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017 Oral Mucositis - Pipeline by Spherium Biomed SL, H1 2017 Oral Mucositis - Dormant Projects, H1 2017 Oral Mucositis - Dormant Projects, H1 2017 (Contd..1), H1 2017 Oral Mucositis - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
